Skip to main content

Table 5 Summary of atorvastatin and doxycycline preclinical data

From: Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models

 

Untreated

Rapamycin

Atorvastatin

Combination Rapamycin plus Atorvastatin

Doxycycline

Combination Rapamycin plus Doxycycline

Number of mice (n)

8

8

8

8

8

8

Median survival (days)

28

41.5

32.5

55.5

28

43

P value (survival)

-

0.003*

NS*

0.0006* NS#

NS*

0.007* NS#

Day 26, average tumor volume (mm3)

1865 ± 532

544 ± 110

1931 ± 298

390 ± 186

1749 ± 352

1117 ± 421

P value (day 26)

-

0.011*

NS*

0.04*

NS*

NS*

Day 42, average tumor volume (mm3)

-

1784 ± 643

-

1188 ± 338

-

2419 ± 570

P value (day 42)

-

-

-

NS#

-

NS#

Rapamycin (IP, 3 days per week)

-

8 mg/kg, 3 days per week

-

8 mg/kg, 3 days per week

-

8 mg/kg, 3 days per week

Atorvastatin (IP, 5 days per week)

-

-

20 mg/kg per day

20 mg/kg per day

-

-

Doxycycline (IP, 5 days per week)

-

-

-

-

10 mg/kg per day

10 mg/kg per day

  1. *compared to untreated
  2. #compared to rapamycin treated
  3. NS, not significant